Curaleaf is entering the New York cannabis market after receiving an approval from the New York State Office of Cannabis Management.
The New York State Office of Cannabis Management (OCM) has granted approval to Curaleaf Holdings, Inc. (Curaleaf) on December 8, 2023, to sell wholesale adult-use cannabis products In the state of the Big Apple, according to a recent press release (1).
Curaleaf is planning to provide five of their premium flower, vape, and edible products that are a part of their Grassroots and Select brand portfolios (1). This includes “Select Briq Essentials, Select X Bites, Select Nano Bites and Grassroots premium flower,” (1). One of Curaleaf’s wholesale partners, MJ Dispensary, who is a Conditional Adult-Use Retail Dispensaries (CAURD) licensee (1), began offering Curaleaf products on December 12, 2023, as an inclusion in their grand opening event in Rochester, New York.
As the company gets further established in the Big Apple state, Curaleaf will develop new products that will be created with “local New York-grown flower, including distillate from New York based hemp farm Open Mind Organics (OMO). Led by David Falkowski, a third-generation farmer who became one of the first licensed hemp farmers in the state,” (1).
“Curaleaf has served New York's medical market with high quality cannabis products and service since 2017, and we are eager to provide that same level of care for the state's adult use customers,” Matt Darin, CEO of Curaleaf, commented (1). “We are pleased that the OCM has taken the next step to allow existing registered operators the opportunity to participate in the adult use market, and we look forward to being among the first as we continue to prioritize our medical patients. We are happy to be working with businesses of all sizes across the state, from hemp farmers to our retail partners, including CAURD licensees, and we aim for statewide distribution by end of year.”
“On our opening day at MJ Dispensary, it's a monumental milestone to be the first licensed New York adult use retail partner to offer our customers access to Select and Grassroots products,” Ryan Martin, CEO of MJ Dispensary, explained (1). “This partnership with Curaleaf is an excellent example of the ways in which the New York market can work together moving forward between large businesses like Curaleaf, and CAURD licensees like MJ Dispensary. Our intention is to support customers with a wide array of products, and we feel we've accomplished that in part due to this partnership.”
Curaleaf is excited to dip their feet into the New York cannabis industry and are inspired to help local communities through their “Rooted in Good” program which work with organizations that handle the challenges caused from the “War on Drugs” (1). The company also is planning to hire, “at least 10% of all new New York hires from populations touched by low-level cannabis-related offenses and hosting retail activations focused on social justice and equity,” reported in the company’s press release (1).
Reference
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.